Literature DB >> 15638876

Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males.

Ki Won Oh1, Eun Jung Rhee, Won Young Lee, Sun Woo Kim, Ki Hyun Baek, Moo Il Kang, Eun Joo Yun, Cheol Young Park, Sung Hee Ihm, Moon Gi Choi, Hyung Joon Yoo, Sung Woo Park.   

Abstract

OBJECTIVE: Osteoporosis is a growing health problem in males as well as in females. Sex hormones and insulin-like growth factor-I (IGF-I) have been shown to be the major determinants in male bone metabolism. Osteoprotegerin (OPG) is a recently identified cytokine that acts as a decoy receptor for the receptor activator of NF-kappaB ligand (RANKL). OPG and RANKL have been shown to be important regulators of osteoclastogenesis. However, the relationship between the OPG-RANKL system and male bone status in human populations are unclear. Thus, the aim of this study was to investigate the relationship between the OPG-RANKL system and bone mineral metabolism in males. PATIENTS AND MEASUREMENTS: Serum concentrations of OPG, RANKL, oestradiol, total testosterone and IGF-I and bone mineral density (BMD) were measured in 80 Korean males aged 42-70 (mean age, 54.5 year). Enzyme-linked immunosorbent assays were used to determine the serum concentrations of OPG and RANKL. Serum concentrations of oestradiol, total testosterone, IGF-I and bone turnover markers were determined using standard methods. BMD at the lumbar spine and femoral neck were measured by dual energy X-ray absorptiometry.
RESULTS: We observed a significant negative correlation between the serum OPG levels and lumbar spine BMD (r =-0.259, P < 0.05) in Spearman correlation analysis. Serum OPG levels and RANKL/OPG ratios were found to be significantly correlated to the serum osteocalcin levels (r =- 0.254, P < 0.05; r = 0.264, P < 0.05) in Spearman correlation analysis. Serum OPG levels were found to be negatively correlated with serum oestradiol levels (r =-0.319, P < 0.01) in Spearman correlation analysis. In addition, a significant positive correlation was found between serum RANKL/OPG ratios and oestradiol levels (r = 0.374, P < 0.001) in Spearman correlation analysis. In contrast, Serum total testosterone and IGF-I levels were not correlated with serum OPG levels or RANKL to OPG ratios in Spearman correlation analysis. In a multiple regression analysis, age, body mass index (BMI), and serum OPG levels were identified as a significant predictor for lumbar spine BMD, and age, BMI, serum OPG and RANKL levels for femoral neck BMD. In another multiple regression analysis, only serum oestradiol level was identified as a significant predictor for serum OPG or RANKL levels. In contrast, Serum total testosterone and IGF-I levels were not correlated with serum OPG or RANKL levels in multiple regression analysis.
CONCLUSIONS: Our data show that the circulating OPG-RANKL system is associated with bone metabolism in the male populations. Also, our data suggest that OPG and RANKL may be mediators of the effects of oestradiol in male bone metabolism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15638876     DOI: 10.1111/j.1365-2265.2004.02179.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  24 in total

1.  Identification of quantitative trait loci affecting body composition in a mouse intercross.

Authors:  James A Vitarius; Ephraim Sehayek; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-18       Impact factor: 11.205

2.  Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.

Authors:  H Dobnig; L C Hofbauer; V Viereck; B Obermayer-Pietsch; A Fahrleitner-Pammer
Journal:  Osteoporos Int       Date:  2006-01-25       Impact factor: 4.507

3.  Detection of rankl positive cells in gingival tissue in healthy & chronic periodontal disease patients-a comparative study.

Authors:  J Bhuvaneswarri; Bagavad Gita; S C Chandrasekaran
Journal:  J Clin Diagn Res       Date:  2014-11-20

4.  A significant association exists between receptor tyrosine kinase-like orphan receptor 2 gene variants and the OPG/RANKL ratio in human plasma.

Authors:  S Ermakov; S Trofimov; I Malkin; G Livshits
Journal:  Osteoporos Int       Date:  2011-11-05       Impact factor: 4.507

5.  Serum osteoprotegerin: bone or cardiovascular marker in Type 2 diabetes males?

Authors:  P Rozas Moreno; R Reyes García; A García-Martín; M Varsavsky; J A García-Salcedo; M Muñoz-Torres
Journal:  J Endocrinol Invest       Date:  2012-02-28       Impact factor: 4.256

6.  Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study.

Authors:  L Jørgensen; A Vik; N Emaus; J Brox; J-B Hansen; E Mathiesen; P Vestergaard
Journal:  Osteoporos Int       Date:  2009-08-22       Impact factor: 4.507

7.  Increased bone resorption is associated with increased risk of cardiovascular events in men: the MINOS study.

Authors:  Pawel Szulc; Elizabeth J Samelson; Douglas P Kiel; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2009-12       Impact factor: 6.741

8.  Elevated ferritin and circulating osteoprotegerin levels as independent predictors of hip fracture in postmenopausal women admitted for fragility fracture: time for new screening strategies?

Authors:  Y Lipovetzki; G Zandman-Goddard; Z Feldbrin; M Shargorodsky
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

9.  Vitamin K, circulating cytokines, and bone mineral density in older men and women.

Authors:  M Kyla Shea; Gerard E Dallal; Bess Dawson-Hughes; José M Ordovas; Christopher J O'Donnell; Caren M Gundberg; James W Peterson; Sarah L Booth
Journal:  Am J Clin Nutr       Date:  2008-08       Impact factor: 7.045

10.  Associations between osteoprotegerin and femoral neck BMD in hemodialysis patients.

Authors:  Konstantinos K Doumouchtsis; Alkis I Kostakis; Stergios K Doumouchtsis; Marios P Tziamalis; Charalambos P Stathakis; Evanthia Diamanti-Kandarakis; Dimitrios Dimitroulis; Despoina N Perrea
Journal:  J Bone Miner Metab       Date:  2008-01-10       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.